Tissue Inhibitor of Metalloproteinase-1 Prevents Cytokine-Mediated Dysfunction and Cytotoxicity in Pancreatic Islets and β-cells
- Leslie and Susan Gonda (Goldschmied) Diabetes and Genetics Research Center, Department of Diabetes, Endocrinology, and Metabolism, City of Hope National Medical Center, Duarte, California
Abstract
In addition to inhibiting matrix metalloproteinase-2 and matrix metalloproteinase-9 activity, recent studies suggest that tissue inhibitor of metalloproteinase (TIMP)-1 may inhibit apoptosis in various cell lines. To address this question in pancreatic islets and β-cells, we treated rat pancreatic islets and INS-1 cells with a high-dose combination of the cytokines interleukin (IL)-1β, tumor necrosis factor-α, and interferon-γ with or without the addition of TIMP-1 and TIMP-2 protein. Using flow cytometry, we quantitated DNA fragmentation to assess cellular apoptosis and confirmed these observations with DNA laddering experiments. Next, we transfected the mouse TIMP-1 gene into INS-1 cells and performed Western immunoblotting to demonstrate expression of TIMP-1 protein. We treated TIMP-1–expressing INS-1 cells with high-dose cytokines and again used flow cytometry to assess DNA fragmentation. We also evaluated the effect of TIMP-1 on IL-1β–induced inhibition of glucose-stimulated insulin secretion (GSIS) in freshly isolated rat pancreatic islets. Finally, we evaluated the effect of TIMP-1 on inducible nitric oxide synthase (iNOS) gene expression and nuclear factor (NF)-κB activity in INS-1 cells stimulated with high-dose cytokines. TIMP-1 but not TIMP-2 prevented cytokine-induced apoptosis and cytokine-mediated inhibition of GSIS in rat islets and β-cells. TIMP-1 mediated these effects by inhibiting cytokine activation of NF-κB, but it did not affect nitric oxide production or iNOS gene expression. Therefore, TIMP-1 may be an ideal gene to prevent cytokine-mediated β-cell destruction and dysfunction in models of type 1 diabetes and islet transplantation rejection.
Footnotes
-
Address correspondence and reprint requests to David Bleich, Department of Diabetes, Endocrinology, and Metabolism, City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010. E-mail: dbleich{at}coh.org.
Received for publication 3 July 2000 and accepted in revised form 9 February 2001.
BSA, bovine serum albumin; EGFP, enhanced green fluorescent protein; FCS, fetal calf serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSIS, glucose-stimulated insulin secretion; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; JAK, Janus kinase; MMP, matrix metalloproteinase; NF, nuclear factor; PBS, phosphate-buffered saline; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinase; TNF, tumor necrosis factor.














